Contact | Print version | PDF version | Send article | RSS feed

BioMS Medical announces receipt of milestone payment from Eli Lilly and Company

US$10 million received based on the positive review of interim analysis for international pivotal multiple sclerosis trial

24 Sep 2008 - BioMS Medical Corp. announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.
 
The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.
 
To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.